BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33063250)

  • 1. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy.
    Guzik P; Benešová M; Ratz M; Monné Rodríguez JM; Deberle LM; Schibli R; Müller C
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):972-983. PubMed ID: 33063250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
    Deberle LM; Benešová M; Becker AE; Ratz M; Guzik P; Schibli R; Müller C
    Bioconjug Chem; 2021 Aug; 32(8):1617-1628. PubMed ID: 34251183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
    Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
    Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
    Busslinger SD; Becker AE; Vaccarin C; Deberle LM; Renz ML; Groehn V; Schibli R; Müller C
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
    Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
    J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
    Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
    Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diastereomerically Pure 6
    Boss SD; Müller C; Siwowska K; Schmid RM; Groehn V; Schibli R; Ametamey SM
    J Nucl Med; 2019 Jan; 60(1):135-141. PubMed ID: 30042162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
    Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
    Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
    Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.
    Müller C; Reber J; Haller S; Dorrer H; Bernhardt P; Zhernosekov K; Türler A; Schibli R
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):476-85. PubMed ID: 24100768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy.
    Reber J; Haller S; Leamon CP; Müller C
    Mol Cancer Ther; 2013 Nov; 12(11):2436-45. PubMed ID: 24030631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising potential of [
    Guzik P; Siwowska K; Fang HY; Cohrs S; Bernhardt P; Schibli R; Müller C
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):984-994. PubMed ID: 33078260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy.
    Guzik P; Fang HY; Deberle LM; Benešová M; Cohrs S; Boss SD; Ametamey SM; Schibli R; Müller C
    J Nucl Med; 2021 Oct; 62(10):1475-1481. PubMed ID: 33452043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity.
    Fischer CR; Groehn V; Reber J; Schibli R; Ametamey SM; Müller C
    Mol Imaging Biol; 2013 Dec; 15(6):649-54. PubMed ID: 23760583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced
    Boss SD; Müller C; Siwowska K; Büchel JI; Schmid RM; Groehn V; Schibli R; Ametamey SM
    Bioconjug Chem; 2018 Apr; 29(4):1119-1130. PubMed ID: 29412638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Properties of
    Larenkov A; Rakhimov M; Lunyova K; Klementyeva O; Maruk A; Machulkin A
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32545327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
    Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
    Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of an innocuous drug cocktail to improve the quality of folic acid targeted nuclear imaging in preclinical research.
    Müller C; Reber J; Schlup C; Leamon CP; Schibli R
    Mol Pharm; 2013 Mar; 10(3):967-74. PubMed ID: 23394590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.